Boehringer’s Spiriva gets UK license for young asthma patients
Boehringer Ingelheim’s Spiriva Respimat is now licensed for use in the UK to treat people with asthma aged six years and older.
Read More
Tag: Respimat
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
